Activation of the 5-hydroxytryptamine 1F receptor alleviated pathological mitochondrial damage through the upregulation of PGC-1α expression and facilitation of mitochondrial biogenesis, which presents a potential therapeutic approach for AKI [97]. This evidence concerns the gene PPARGC1A and acute kidney injury.